This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.

Please refer to detailed description in the following context.

Inclusion Criteria:

• The written informed consent of the patients has been obtained before any examination, sampling and analysis related to the study.
• Primary lung adenocarcinoma diagnosed histologically/cytologically.
• Stages IIIA-IIIB (N1-N2) according to the AJCC 8th edition lung cancer stage and plan to receive radical excision judged by investigators.
• EGFR mutation positive (19Del or L858R, with or without T790M)
• The presence of at least one measurable lesion and suitable for accurate repeated measurements.
• ECOG performance status 0-1.
• For premenopausal women with fertility, the result of serum or urine pregnancy test should be negative within 7 days before the first dose.

Exclusion Criteria:

• Squamous cell carcinoma, and tumors with neuroendocrine components such as large cell carcinoma, or small cell carcinoma.
• Patients with EGFR exon 20 insertion mutation.
• Exposure to other antitumor therapies prior to enrolment.
• Major surgery was performed in the four weeks prior to the first dosing of the study drug.
• Pregnant or lactating female patients.
• Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days prior to initial administration.
• Have a history of or present complications with other malignancies.
• Patients with severe or uncontrolled systemic disease requiring treatment were not considered suitable for the study.
• ECG QT interval prolongation or associated risk.
• A history of interstitial pneumonia or related risk.
• Inadequate bone marrow or organ reserve.
• Other circumstances that are not suitable for participation in this study.

The IPD sharing plan is not to be shared according to the policy.